ZA905312B - Combination therapy for prohylaxsis and/or treatment of benign prostatic hyperplasia - Google Patents

Combination therapy for prohylaxsis and/or treatment of benign prostatic hyperplasia

Info

Publication number
ZA905312B
ZA905312B ZA905312A ZA905312A ZA905312B ZA 905312 B ZA905312 B ZA 905312B ZA 905312 A ZA905312 A ZA 905312A ZA 905312 A ZA905312 A ZA 905312A ZA 905312 B ZA905312 B ZA 905312B
Authority
ZA
South Africa
Prior art keywords
treatment
benign prostatic
prostatic hyperplasia
prohylaxsis
combination therapy
Prior art date
Application number
ZA905312A
Other languages
English (en)
Inventor
Fernand Labrie
Labrie Fernand
Original Assignee
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorecherche Inc filed Critical Endorecherche Inc
Publication of ZA905312B publication Critical patent/ZA905312B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fertilizers (AREA)
  • Medicinal Preparation (AREA)
ZA905312A 1989-07-07 1990-07-06 Combination therapy for prohylaxsis and/or treatment of benign prostatic hyperplasia ZA905312B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37670089A 1989-07-07 1989-07-07

Publications (1)

Publication Number Publication Date
ZA905312B true ZA905312B (en) 1992-02-26

Family

ID=23486098

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA905312A ZA905312B (en) 1989-07-07 1990-07-06 Combination therapy for prohylaxsis and/or treatment of benign prostatic hyperplasia

Country Status (17)

Country Link
US (1) US5817649A (ja)
EP (3) EP0943328B1 (ja)
JP (2) JP3332377B2 (ja)
KR (1) KR920703063A (ja)
AT (2) ATE177949T1 (ja)
AU (2) AU643445B2 (ja)
CA (1) CA2062973C (ja)
DE (2) DE69034148T2 (ja)
DK (2) DK0943328T3 (ja)
ES (2) ES2133270T3 (ja)
HU (1) HU223662B1 (ja)
IE (2) IE990530A1 (ja)
IL (1) IL94990A (ja)
MY (1) MY106484A (ja)
NZ (1) NZ234414A (ja)
WO (1) WO1991000731A1 (ja)
ZA (1) ZA905312B (ja)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
EP0595796B1 (en) * 1989-07-07 2003-01-15 Endorecherche Inc. Method of treatment of androgen-related diseases
IL101245A0 (en) * 1991-03-20 1992-11-15 Merck & Co Inc Pharmaceutical compositions for the treatment of prostatic cancer
WO1992018132A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
GB9506678D0 (en) * 1995-03-31 1995-05-24 Glaxo Inc Substituted 6-azacholesten-3-ones
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
HUP0101809A3 (en) 1998-03-11 2002-07-29 Endorech Inc Sainte Foy Inhibitors of type 5 and type 3 17betha-hydroxysteroid dehydrogenase and methods for their use
EP1321146A3 (en) * 1998-03-11 2004-06-02 Endorecherche Inc. Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
US6268377B1 (en) * 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
BR0013272B1 (pt) 1999-08-13 2013-10-15 Uso de um inibidor de aromatase esteroidal
US6200573B1 (en) 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1299094A2 (en) 2000-06-28 2003-04-09 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
AU2001267904A1 (en) * 2000-06-30 2002-01-14 Chugai Seiyaku Kabushiki Kaisha Novel antiandrogenic agent
EP1854798A3 (en) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2002089802A2 (en) 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
WO2003005889A2 (en) * 2001-07-10 2003-01-23 Ams Research Corporation Surgical kit for treating prostate tissue
WO2003022835A1 (en) 2001-09-06 2003-03-20 Schering Corporation 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
PE20030705A1 (es) 2001-10-17 2003-08-21 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes
ES2310622T3 (es) 2001-12-19 2009-01-16 Bristol-Myers Squibb Company Compuestos heterociclicos condensados y analogos de los mismos, moduladores de la funcion de los receptores nucleares de hormonas.
CN100374421C (zh) 2002-11-18 2008-03-12 先灵公司 用于治疗雄激素依赖性疾病的3型17β-羟基类固醇脱氢酶抑制剂
ES2312845T3 (es) 2002-12-17 2009-03-01 Schering Corporation Inhibidores de la deshidrogenasa de 17 beta-hidroxiesteroides de tipo 3 para el tratamiento de enfermedades dependientes de androgenos.
US20060258628A1 (en) * 2004-07-20 2006-11-16 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof
BRPI0516243C1 (pt) 2004-10-20 2021-05-25 Endorecherche Inc uso de um precursor de esteróide sexual selecionado do grupo que consiste em dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-5-eno-3b,17b-diol e 4-androsten-3,17-diona, uso do referido precursor em 5 associação com um modulador de receptor de estrogênio seletivo para proteção uterina e da glândula mamária contra câncer, composição farmacêutica e kit
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
EP3510959B1 (en) 2007-01-02 2021-03-03 AquaBeam LLC Minimally invasive devices for the treatment of prostate diseases
US9232959B2 (en) 2007-01-02 2016-01-12 Aquabeam, Llc Multi fluid tissue resection methods and devices
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound
EP2259742B1 (en) 2008-03-06 2020-01-01 AquaBeam LLC Tissue ablation and cautery with optical energy carried in fluid stream
US9848904B2 (en) 2009-03-06 2017-12-26 Procept Biorobotics Corporation Tissue resection and treatment with shedding pulses
JP2015508825A (ja) * 2012-02-29 2015-03-23 レプロス セラピューティクス インコーポレイティド アンドロゲン欠乏症を治療するための併用療法
ES2687817T3 (es) 2012-02-29 2018-10-29 Procept Biorobotics Corporation Resección y tratamiento de tejido guiado por imagen automatizada
JP6403695B2 (ja) 2013-02-14 2018-10-10 プロセプト バイオロボティクス コーポレイション アクアアブレーションアクアビーム眼科手術方法および装置
JP6461971B2 (ja) 2013-09-06 2019-01-30 プロセプト バイオロボティクス コーポレイション 飛散パルスを用いた組織切除および処置
JP6651471B2 (ja) 2014-06-30 2020-02-19 プロセプト バイオロボティクス コーポレイション 流体ジェット組織アブレーションおよび冷凝固（ａｑｕａｂｌａｔｉｏｎ）方法および装置
CN107072591B (zh) 2014-09-05 2021-10-26 普罗赛普特生物机器人公司 与靶器官图像的治疗映射结合的医师控制的组织切除

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329364A (en) * 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4039669A (en) * 1975-08-01 1977-08-02 Sterling Drug Inc. Composition for topical application and use thereof
US4087461A (en) * 1976-02-26 1978-05-02 The Johns Hopkins University Anti-androgenic steroids
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
US4235893A (en) * 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
FR2465486A1 (fr) * 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
DE3121153A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
US4347363A (en) * 1981-09-17 1982-08-31 Sterling Drug Inc. Process for preparing 1,2-dihydro-6-methyl-2-oxo-5-(pyridinyl)nicotinonitriles
DE3339295A1 (de) * 1982-11-15 1984-05-17 Schering AG, 1000 Berlin und 4709 Bergkamen 4-hydroxy- und 4-acyloxy-4-androsten-3,17-dione zur verwendung bei der prophylaxe und therapie der prostatahyperplasie und diese enthaltende mittel fuer derartige verwendung
GR79447B (ja) * 1982-12-31 1984-10-30 Mortimer Christopher H Dr
DE3323321A1 (de) * 1983-06-24 1985-01-03 Schering AG, 1000 Berlin und 4709 Bergkamen Prophylaxe und therapie von koronaren herzkrankheiten durch senkung des oestrogenspiegels
WO1985002543A1 (en) * 1983-12-12 1985-06-20 Kaszynski Edwin G Hair growth modification
US4684635A (en) * 1984-05-11 1987-08-04 Norman Orentreich Compositions and methods for inhibiting the action of androgens
US5053403A (en) * 1984-05-11 1991-10-01 Norman Orentreich Methods for treatment of male-pattern baldness
WO1986001105A1 (en) * 1984-08-02 1986-02-27 Fernand Labrie Pharmaceutical composition for combination therapy of hormone dependent cancers
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
EP0177654B1 (fr) * 1984-10-10 1989-05-31 Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France Association synergique contraceptive
GB8503940D0 (en) * 1985-02-15 1985-03-20 Erba Farmitalia 4-substituted androstendione derivatives
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
DE3607651A1 (de) * 1986-03-06 1987-09-10 Schering Ag Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer
IE60964B1 (en) * 1986-12-11 1994-09-07 Roussel Uclaf Zootechnical compositions containing a beta-adrenergic
US4888336A (en) * 1987-01-28 1989-12-19 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
DE3888378T2 (de) * 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia

Also Published As

Publication number Publication date
ATE177949T1 (de) 1999-04-15
AU668434B2 (en) 1996-05-02
EP0480950A1 (en) 1992-04-22
IE902459A1 (en) 1991-02-13
ES2222633T3 (es) 2005-02-01
IL94990A0 (en) 1991-06-10
EP0857487A3 (en) 1999-12-08
DE69034148T2 (de) 2005-06-30
HU9200047D0 (en) 1992-06-29
EP0943328A2 (en) 1999-09-22
DE69034148D1 (de) 2004-07-22
EP0480950B1 (en) 1999-03-24
EP0943328A3 (en) 1999-12-08
JP2001354590A (ja) 2001-12-25
HUT60138A (en) 1992-08-28
ES2133270T3 (es) 1999-09-16
DK0480950T3 (da) 1999-10-11
AU5217493A (en) 1994-02-10
HU223662B1 (hu) 2004-11-29
IE990530A1 (en) 2000-11-15
AU5854590A (en) 1991-02-06
CA2062973C (en) 2003-09-23
MY106484A (en) 1995-05-30
CA2062973A1 (en) 1991-01-08
DE69033020D1 (de) 1999-04-29
IE990531A1 (en) 2000-11-15
KR920703063A (ko) 1992-12-17
NZ234414A (en) 1999-05-28
EP0857487A2 (en) 1998-08-12
AU643445B2 (en) 1993-11-18
DK0943328T3 (da) 2004-10-18
IL94990A (en) 1997-01-10
JP3332377B2 (ja) 2002-10-07
US5817649A (en) 1998-10-06
DE69033020T2 (de) 1999-08-05
WO1991000731A1 (en) 1991-01-24
ATE269066T1 (de) 2004-07-15
JPH04506798A (ja) 1992-11-26
EP0943328B1 (en) 2004-06-16

Similar Documents

Publication Publication Date Title
ZA905312B (en) Combination therapy for prohylaxsis and/or treatment of benign prostatic hyperplasia
MX9702380A (es) Nuevas carboxamidas con actividad antifungica.
IL87885A (en) Pharmaceutical compositions having antiprogestational and anti-estrogenic activities for the treatment of hormone- dependent tumors
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
EP1903057A3 (en) Lipoprotein-regulating medicaments
CA2245142A1 (en) New phenanthridines
GEP20033025B (en) 4,4-Biarylpiperidine Derivatives with Opioid Receptor Activity
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
IL101574A0 (en) Combination pharmaceutical compositions for the treatment of benign prostatic hyperplasia
MX9604434A (es) Productos farmaceuticos y medicamentos para la prevencion y el tratamiento de disfunciones endoteliales.
DE3875866D1 (de) Sulfonamidolphenyl-derivate und diese enthaltende therapeutische und vorbeugend wirkende mittel gegen arrhythmie.
MX9504023A (es) Composicion farmaceutica y transdermicamente activa que contiene acido 5-aminolaevulinico y procedimiento para su preparacion.
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
NO911022L (no) Fremgangsmaate og preparat for oeket hudkonsentrasjon av aktive bestanddeler ved iontoforese.
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
ATE82855T1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosidphosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.